Participants enrolled into randomized controlled trials (RCTs) often do not reflect real-world populations. Previous research in how best to translate RCT results to target populations has focused on weighting RCT data to look like the target data. Simulation work, however, has suggested that an outcome model approach may be preferable. Here we describe such an approach using source data from the 2x2 factorial NAVIGATOR trial which evaluated the impact of valsartan and nateglinide on cardiovascular outcomes and new-onset diabetes in a "pre-diabetic" population. Our target data consisted of people with "pre-diabetes" serviced at our institution. We used Random Survival Forests to develop separate outcome models for each of the 4 treatments, estimating the 5-year risk difference for progression to diabetes and estimated the treatment effect in our local patient populations, as well as sub-populations, and the results compared to the traditional weighting approach. Our models suggested that the treatment effect for valsartan in our patient population was the same as in the trial, whereas for nateglinide treatment effect was stronger than observed in the original trial. Our effect estimates were more efficient than the weighting approach.
|Original language||English (US)|
|State||Published - Jun 25 2018|
ASJC Scopus subject areas